KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets (2016 - 2025)

Jazz Pharmaceuticals has reported Other Non-Current Assets over the past 16 years, most recently at $99.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $99.0 million for Q4 2025, down 13.5% from a year ago — trailing twelve months through Dec 2025 was $99.0 million (down 13.5% YoY), and the annual figure for FY2025 was $99.0 million, down 13.5%.
  • Other Non-Current Assets for Q4 2025 was $99.0 million at Jazz Pharmaceuticals, up from $8.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for JAZZ hit a ceiling of $121.3 million in Q2 2025 and a floor of $4.4 million in Q3 2024.
  • Median Other Non-Current Assets over the past 5 years was $32.5 million (2021), compared with a mean of $43.2 million.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 90.97% in 2024 and later surged 2014.21% in 2025.
  • Jazz Pharmaceuticals' Other Non-Current Assets stood at $40.8 million in 2021, then surged by 35.1% to $55.1 million in 2022, then rose by 22.35% to $67.5 million in 2023, then skyrocketed by 69.69% to $114.5 million in 2024, then fell by 13.5% to $99.0 million in 2025.
  • The last three reported values for Other Non-Current Assets were $99.0 million (Q4 2025), $8.0 million (Q3 2025), and $121.3 million (Q2 2025) per Business Quant data.